文献速递白血病

伴TP53基因突变或17p染色体缺失的急性髓系白血病患者的临床特征与总生存期

Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion.
PubMed 文献 · Am J Hematol · 2023-05-04

基于全国性真实世界数据库纳入370例新诊断伴TP53突变或17p缺失的急性髓系白血病成人患者,按一线方案分为维奈克拉联合去甲基化药物、强化化疗、去甲基化药物单用三组,中位总生存期分别为7.4、9.4、5.9个月,校正协变量后不同治疗类型间生存无差异,总体结局不佳。

要点

  • 370例中TP53突变124例、17p缺失166例、两者兼有80例,中位年龄72岁。
  • 一线治疗后骨髓缓解(原始细胞<5%)总体54%(115/215),三组分别为67%、62%、19%。
  • 中位总生存期A组7.4个月、B组9.4个月、C组5.9个月;校正后组间无差异。

核心结论

  • 伴TP53突变或17p缺失的急性髓系白血病患者在当前治疗下结局不佳,存在高度未满足的改进治疗需求。

研究设计与样本

  • 基于全国性、去标识化真实世界数据库纳入年龄≥18岁的新诊断急性髓系白血病成人患者。
  • 共纳入370例伴TP53突变(n=124)、17p缺失(n=166)或两者兼有(n=80)的患者。
  • 接受一线治疗者分为三组:维奈克拉联合去甲基化药物(A组)、强化化疗(B组)、去甲基化药物不联合维奈克拉(C组)。

主要发现

  • 中位年龄72岁(范围24-84岁);男性占59%,白人占69%。
  • 基线骨髓原始细胞≤30%、31%-50%、>50%者在A、B、C组分别占41%、24%、29%(原文此处将三个区间对应至三组,按原文照录)。
  • 一线治疗后骨髓缓解(原始细胞<5%)总体54%(115/215),A组67%(38/57)、B组62%(68/110)、C组19%(9/48)。
  • 中位骨髓缓解持续时间A组6.3个月、B组6.9个月、C组5.4个月。
  • 中位总生存期(95%CI)A组7.4个月(6.0-8.8)、B组9.4个月(7.2-10.4)、C组5.9个月(4.3-7.5)。

关键数值与推荐

  • 校正相关协变量后不同治疗类型间生存无差异:A组 vs C组校正风险比(aHR)=0.9,95%CI 0.7-1.3;A组 vs B组aHR=1.0,95%CI 0.7-1.5;C组 vs B组aHR=1.1,95%CI 0.8-1.6。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Approximately 5% to 15% of acute myeloid leukemia (AML) patients have TP53 gene mutations (TP53m), which are associated with very poor outcomes. Adults (≥18 years) with a new AML diagnosis were included from a nationwide, de-identified, real-world database. Patients receiving first-line therapy were divided into three cohorts: venetoclax (VEN) + hypomethylating agents (HMAs; Cohort A), intensive chemotherapy (Cohort B), or HMA without VEN (Cohort C). A total of 370 newly diagnosed AML patients with TP53m (n = 124), chromosome 17p deletion (n = 166), or both (n = 80) were included. The median age was 72 years (range, 24-84); most were male (59%) and White (69%). Baseline bone marrow (BM) blasts were ≤30%, 31%-50%, and >50% in 41%, 24%, and 29% of patients in Cohorts A, B, and C, respectively. BM remission (<5% blasts) with first-line therapy was reported in 54% of patients (115/215) overall, and 67% (38/57), 62% (68/110), and 19% (9/48) for respective cohorts (median BM remission duration: 6.3, 6.9, and 5.4 months). Median overall survival (95% CI) was 7.4 months (6.0-8.8) for Cohort A, 9.4 months (7.2-10.4) for Cohort B, and 5.9 months (4.3-7.5) for Cohort C. There were no differences in survival by treatment type after adjusting for the effects of relevant covariates (Cohort A vs. C adjusted hazard ratio [aHR] = 0.9; 95% CI, 0.7-1.3; Cohort A vs. B aHR = 1.0; 95% CI, 0.7-1.5; and Cohort C vs. B aHR = 1.1; 95% CI, 0.8-1.6). Patients with TP53m AML have dismal outcomes with current therapies, demonstrating the high unmet need for improved treatments.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Daver NG, Iqbal S, Huang J, et al. Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion. Am J Hematol. 2023. PMID: 37139921. doi:10.1002/ajh.26941

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。